Oxford BioMedica Annual General Meeting

RNS Number : 4651A

Oxford Biomedica PLC

07 June 2016

 

Oxford BioMedica Annual General Meeting

London, UK - 7 June 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:

·      Resolution 9: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares; and

·      Resolution 10: to permit the Group to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.

Certified copies of the document setting out the above resolutions passed at the 2016 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.

The results of the proxy voting in advance of the meeting are shown below.  On the Record Date (3 June 2016) there were 2,703,149,291 1p ordinary shares in issue, each carrying one vote per share.

Resolution	Votes For	Votes at Chairman's Discretion	Votes at other proxy Discretion	Votes Against	Votes Withheld	Total votes cast	Result
Ordinary resolutions
1	1,485,649,973	3,312,033	2,846,516	38,490	33,512	1,491,880,524	Passed
2	1,476,569,089	3,441,302	2,846,516	1,251,449	7,772,168	1,491,880,524	Passed
3	1,485,481,782	3,315,455	2,846,516	74,890	145,180	1,491,863,823	Passed
4	1,483,363,810	3,326,126	2,846,516	2,134,604	209,468	1,491,880,524	Passed
5	1,370,961,344	3,315,455	2,846,516	111,174,129	3,583,080	1,491,880,524	Passed
6	1,485,446,226	3,355,455	2,846,516	87,809	144,518	1,491,880,524	Passed
7	1,395,088,017	3,321,608	2,846,516	87,748,985	2,875,398	1,491,880,524	Passed
8	1,485,136,315	3,389,372	2,846,516	443,395	64,926	1,491,880,524	Passed
Special resolutions
9	1,484,857,700	3,403,028	2,846,516	663,953	109,327	1,491,880,524	Passed
10	1,483,284,959	3,449,017	2,846,516	2,194,336	105,696	1,491,880,524	Passed

- Ends -

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

RAGEAAKXEFDKEFF